| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
INSERM E 0345, EFS-Alsace, 10 rue Spielmann, BP 36, 67065 Strasbourg Cédex, France
Correspondence
Robert Drillien
robert.drillien{at}efs-alsace.fr
Modified vaccinia virus Ankara (MVA) is a highly attenuated strain known to be an effective vaccine vector. Here it is demonstrated that MVA, unlike standard vaccinia virus (VACV) strains, activates monocyte-derived human dendritic cells (DCs) as testified by an increase in surface co-stimulatory molecules and the secretion of pro-inflammatory cytokines. Inhibition of virus gene expression by subjecting MVA to UV light or heat treatment did not alter its ability to activate DCs. On the other hand, standard VACV strains activated DCs if virus gene expression was prevented by prior UV light or heat treatment. These results suggest that MVA or standard VACV particles are responsible for DC activation but, in the case of standard VACV strains, virus gene expression prevents activation. Additional experiments showed that DCs were activated by MVA-infected HeLa cells and, under these conditions, could induce secretion of gamma interferon from T lymphocytes more efficiently than if a replication-competent VACV strain was employed. These data provide one explanation for the remarkable immune-stimulating capacity of MVA in the absence of virus multiplication.
This article has been cited by other articles:
|
|
 |
|
  Z. Waibler, M. Anzaghe, T. Frenz, A. Schwantes, C. Pohlmann, H. Ludwig, M. Palomo-Otero, A. Alcami, G. Sutter, and U. Kalinke Vaccinia Virus-Mediated Inhibition of Type I Interferon Responses Is a Multifactorial Process Involving the Soluble Type I Interferon Receptor B18 and Intracellular Components J. Virol., February 15, 2009; 83(4): 1563 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Teoh, L. A. Johnson, T. Hanke, A. J. McMichael, and D. G. Jackson Blocking Development of a CD8+ T Cell Response by Targeting Lymphatic Recruitment of APC J. Immunol., February 15, 2009; 182(4): 2425 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Waibler, M. Anzaghe, H. Ludwig, S. Akira, S. Weiss, G. Sutter, and U. Kalinke Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses J. Virol., November 15, 2007; 81(22): 12102 - 12110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yang, T. Dong, E. Turnbull, S. Ranasinghe, B. Ondondo, N. Goonetilleke, N. Winstone, K. di Gleria, P. Bowness, C. Conlon, et al. Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy J. Immunol., July 1, 2007; 179(1): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Deng, P. Dai, W. Ding, R. D. Granstein, and S. Shuman Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J. Virol., October 1, 2006; 80(20): 9977 - 9987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Cottingham, A. van Maurik, M. Zago, A. T. Newton, R. J. Anderson, M. K. Howard, J. Schneider, and M. A. Skinner Different Levels of Immunogenicity of Two Strains of Fowlpox Virus as Recombinant Vaccine Vectors Eliciting T-Cell Responses in Heterologous Prime-Boost Vaccination Strategies. Clin. Vaccine Immunol., July 1, 2006; 13(7): 747 - 757. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
